Adaptive Biotechnologies Corporation has announced two non-exclusive agreements with Pfizer Inc. The first is a target discovery agreement in which Adaptive will identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis $(RA)$ using its immune medicine platform. Pfizer will be responsible for the development and commercialization of any therapies that result from this work. Adaptive will receive an upfront payment and may be eligible for additional milestone payments totaling up to approximately $890 million. The second agreement is a data licensing deal granting Pfizer access to Adaptive's proprietary TCR-antigen datasets. This data will be used by Pfizer to develop and train artificial intelligence and machine learning models for research and drug discovery in multiple disease areas. Adaptive will receive an upfront payment and potential annual licensing fees under this multi-year, non-exclusive agreement. Specific financial terms for the data licensing arrangement were not disclosed.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptive Biotechnologies Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9602009-en) on December 15, 2025, and is solely responsible for the information contained therein.
Comments